Pien Tze Huang suppresses IL-6-inducible STAT3 activation in human colon carcinoma cells through induction of SOCS3

Oncology Reports

Volumn 28, Issue 6, 2012, Pages 2125-2130

  Shen, Aling ^a   Chen, Youqin ^b   Hong, Fei ^c   Lin, Jiumao ^a   Wei, Lihui ^a   Hong, Zhenfeng ^a   Sferra, Thomas J ^b   Peng, Jun ^a,c  

^a FUJIAN UNIVERSITY OF TRADITIONAL CHINESE MEDICINE   (China)

^b CASE WESTERN RESERVE UNIVERSITY   (United States)

^c Zhangzhou Pien Tze Huang Pharmaceutical Co Ltd   (China)

Author keywords

Colorectal cancer; IL 6 STAT3 pathway; Pien Tze Huang; SOCS3; Traditional Chinese medicine

Indexed keywords

CHINESE DRUG; CYCLIN D; INTERLEUKIN 6; PIEN TZE HUANG; PROTEIN BCL 2; STAT3 PROTEIN; SUPPRESSOR OF CYTOKINE SIGNALING 3; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; CARCINOMA CELL; CELL PROLIFERATION; CELL STRAIN HT29; COLON CARCINOMA; CONFERENCE PAPER; DOSE RESPONSE; GENE TARGETING; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN INDUCTION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; UPREGULATION;

APOPTOSIS; CELL LINE, TUMOR; CELL PROLIFERATION; COLONIC NEOPLASMS; CYCLIN D1; DRUGS, CHINESE HERBAL; HUMANS; INTERLEUKIN-6; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS C-BCL-2; SIGNAL TRANSDUCTION; STAT3 TRANSCRIPTION FACTOR; SUPPRESSOR OF CYTOKINE SIGNALING PROTEINS; TRANSCRIPTION, GENETIC; UP-REGULATION;

EID: 84868096612     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2012.2067     Document Type: Conference Paper

References (40)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E and Forman D: Global cancer statistics. CA Cancer J Clin 61:69-90, 2011.
2. Belluco C, Nitti D, Frantz M, Toppan P, Basso D, Plebani M, Lise M and Jessup JM: Interleukin-6 blood level is associated with circulating carcinoembryonic antigen and prognosis in patients with colorectal cancer. Ann Surg Oncol 7:133-138, 2000. (Pubitemid 30164682)
3. Komoda H, Tanaka Y, Honda M, Matsuo Y, Hazama K and Takao T: Interleukin-6 levels in colorectal cancer tissues. World J Surg 22:895-898, 1998. (Pubitemid 28322091)
4. Galizia G, Orditura M, Romano C, Lieto E, Castellano P, Pelosio L, Imperatore V, Catalano G, Pignatelli C and De Vita F: Prognostic significance of circulating IL-10 and IL-6 serum levels in colon cancer patients undergoing surgery. Clin Immunol 102:169-178, 2002. (Pubitemid 34171516)
5. Schneider MR, Hoeflich A, Fischer JR, Wolf E, Sordat B and Lahm H: Interleukin-6 stimulates clonogenic growth of primary and metastatic human colon carcinoma cells. Cancer Lett 151:31-38, 2000. (Pubitemid 30155582)
6. Becker C, Fantini MC, Schramm C, Lehr HA, Wirtz S, Nikolaev A, Burg J, Strand S, Kiesslich R, Huber S, et al: TGF-beta suppresses tumor progression in colon cancer by inhibition of IL-6 transsignaling. Immunity 2:491-501, 2004. (Pubitemid 39370505)
7. Becker C, Fantini MC, Wirtz S, Nikolaev A, Lehr HA, Galle PR, Rose-John S and Neurath MF: IL-6 signaling promotes tumor growth in colorectal cancer. Cell Cycle 4:217-220, 2005. (Pubitemid 41365319)
8. Dowdall JF, Winter DC, Andrews E, Laug WE, Wang JH and Redmond HP: Soluble interleukin 6 receptor (sIL-6R) mediates colonic tumor cell adherence to the vascular endothelium: a mechanism for metastatic initiation? J Surg Res 107:1-6, 2002. (Pubitemid 35191805)
9. Heinrich PC, Behrmann I, Haan S, Hermanns HM, Müller-Newen G and Schaper F: Principles of interleukin (IL)-6-type cytokine signalling and its regulation. Biochem J 374:1-20, 2003. (Pubitemid 37046923)
10. Bromberg J and Darnell JE Jr: The role of STATs in transcriptional control and their impact on cellular function. Oncogene 19:2468-2473, 2000. (Pubitemid 30339202)
11. Aggarwal BB, Kunnumakkara AB, Harikumar KB, Gupta SR, Tharakan ST, Koca C, Dey S, and Sung B: Signal transducer and activator of transcription-3, inflammation, and cancer: how intimate is the relationship? Ann NY Acad Sci 1171:59-76, 2009.
12. Darnell JE Jr: STATs and gene regulation. Science 277:1630-1635, 1997. (Pubitemid 27446219)
13. Zushi S, Shinomura Y, Kiyohara T, Miyazaki Y, Kondo S, Sugimachi M, Higashimoto Y, Kanayama S and Matsuzawa Y: STAT3 mediates the survival signal in oncogenic ras-transfected intestinal epithelial cells. Int J Cancer 78:326-330, 1998. (Pubitemid 28445370)
14. Masuda M, Suzui M, Yasumatu R, Nakashima T, Kuratomi Y, Azuma K, Tomita K, Komiyama S and Weinstein IB: Constitutive activation of signal transducers and activators of transcription 3 correlates with cyclin D1 overexpression and may provide a novel prognostic marker in head and neck squamous cell carcinoma. Cancer Res 62:3351-3355, 2002. (Pubitemid 34651376)
15. Bromberg J and Wang TC: Inflammation and cancer: IL-6 and STAT3 complete the link. Cancer Cell 15:79-80, 2009.
16. Kusaba T, Nakayama T, Yamazumi K, Yakata Y, Yoshizaki A, Inoue K, Nagayasu T and Sekine I: Activation of STAT3 is a marker of poor prognosis in human colorectal cancer. Oncol Rep 15:1445-1451, 2006.
17. Lin Q, Lai R, Chirieac LR, Li C, Thomazy VA, Grammatikakis I, Rassidakis GZ, Zhang W, Fujio Y, Kunisada K, Hamilton SR and Amin HM: Constitutive activation of JAK3/STAT3 in colon carcinoma tumors and cell lines: inhibition of JAK3/STAT3 signaling induces apoptosis and cell cycle arrest of colon carcinoma cells. Am J Pathol 167:969-980, 2005. (Pubitemid 41416250)
18. Xiong H, Zhang Z, Tian X, Sun D, Liang Q, Zhang Y, Lu R, Chen Y and Fang J: Inhibition of JAK1, 2/STAT3 signaling induces apoptosis, cell cycle arrest, and reduces tumor cell invasion in colorectal cancer cells. Neoplasia 10:287-297, 2008. (Pubitemid 351328587)
19. Endo TA, Masuhara M, Yokouchi M, Suzuki R, Sakamoto H, Mitsui K, Matsumoto A, Tanimura S, Ohtsubo M, Misawa H, et al: A new protein containing an SH2 domain that inhibits JAK kinases. Nature 387:921-924, 1997. (Pubitemid 27289595)
20. Hilton DJ, Richardson RT, Alexander WS, Viney EM, Willson TA, Sprigg NS, Starr R, Nicholson SE, Metcalf D and Nicola NA: Twenty proteins containing a C-terminal SOCS box form five structural classes. Proc Natl Acad Sci USA 95:114-119, 1998. (Pubitemid 28103916)
21. Naka T, Narazaki M, Hirata M, Matsumoto T, Minamoto S, Aono A, Nishimoto N, Kajita T, Taga T, Yoshizaki K, et al: Structure and function of a new STAT-induced STAT inhibitor. Nature 387:924-929, 1997. (Pubitemid 27289596)
22. Starr R, Willson TA, Viney EM, Murray LJ, Rayner JR, Jenkins BJ, Gonda TJ, Alexander WS, Metcalf D, Nicola NA and Hilton DJ: A family of cytokine-inducible inhibitors of signalling. Nature 387:917-921, 1997. (Pubitemid 27289594)
23. He B, You L, Uematsu K, Zang K, Xu Z, Lee AY, Costello JF, McCormick F and Jablons DM: SOCS-3 is frequently silenced by hypermethylation and suppresses cell growth in human lung cancer. Proc Natl Acad Sci USA 100:14133-14138, 2003. (Pubitemid 37499203)
24. Oshimo Y, Kuraoka K, Nakayama H, Kitadai Y, Yoshida K, Chayama K and Yasui W: Epigenetic inactivation of SOCS-1 by CpG island hypermethylation in human gastric carcinoma. Int J Cancer 112:1003-1009, 2004. (Pubitemid 39507006)
25. Sutherland KD, Lindeman GJ, Choong DY, Wittlin S, Brentzell L, Phillips W, Campbell IG and Visvader JE: Differential hypermethylation of SOCS genes in ovarian and breast carcinomas. Oncogene 23:7726-7733, 2004. (Pubitemid 39424931)
26. Rigby RJ, Simmons JG, Greenhalgh CJ, Alexander WS and Lund PK: Suppressor of cytokine signaling 3 (SOCS3) limits damage-induced crypt hyper-proliferation and inflammation-associated tumorigenesis in the colon. Oncogene 26:4833-4841, 2007. (Pubitemid 47093177)
27. Gustin DM and Brenner DE: Chemoprevention of colon cancer: current status and future prospects. Cancer Metastasis Rev 21:323-348, 2002. (Pubitemid 36071919)
28. Gorlick R and Bertino JR: Drug resistance in colon cancer. Semin Oncol 26:606-611, 1999. (Pubitemid 30013267)
29. Longley DB, Allen WL and Johnston PG: Drug resistance, predictive markers and pharmacogenomics in colorectal cancer. Biochim Biophys Acta 1766:184-196, 2006.
30. Boose G and Stopper H: Genotoxicity of several clinically used topoisomerase II inhibitors. Toxicol Lett 116:7-16, 2000. (Pubitemid 30440762)
31. Newman DJ, Cragg GM and Snader KM: The influence of natural products upon drug discovery. Nat Prod Rep 17:215-234, 2000. (Pubitemid 30390787)
32. Gordaliza M: Natural products as leads to anticancer drugs. Clin Transl Oncol 9:767-776, 2007.
33. Lin JM, Chen YQ, Wei LH, Chen XZ, Xu W, Hong ZF, Sferra TJ and Peng J: Hedyotis Diffusa Willd extract induces apoptosis via activation of the mitochondrion-dependent pathway in human colon carcinoma cells. Int J Oncol 37:1331-1338, 2010.
34. Chinese Pharmacopoeia Commission. Pharmacopoeia of the Peoples Republic of China. Vol 1 Chinese Medical Science and Technology Press, Beijing, pp573-575, 2010.
35. Xu YY and Yu EX: Clinical analysis of the effect of Pien Tze Huang in treatment of 42 patients with moderate or advanced liver cancer. Shanghai J Tradit Chin Med 12:4-5, 1994.
36. Gu ZX: Therapeutical observation of advanced colon cancer. Chin Tradit Patent Med 15:23, 1993.
37. Lin JM, Wei LH, Chen YQ, Liu XX, Hong ZF, Sferra TJ and Peng J: Pien Tze Huang-induced apoptosis in human colon cancer HT-29 cells is associated with regulation of the Bcl-2 family and activation of caspase 3. Chin J Integr Med 17:685-690, 2011.
38. Zhuang QC, Hong F, Shen AL, Zheng LP, Zeng JW, Lin W, Chen YQ, Sferra TJ, Hong ZF and Peng J: Pien Tze Huang inhibits tumor cell proliferation and promotes apoptosis via suppressing the STAT3 pathway in a colorectal cancer mouse model. Int J Oncol 40:1569-1574, 2012.
39. Schmitz J, Weissenbach M, Haan S, Heinrich PC and Schaper F: SOCS3 exerts its inhibitory function on interleukin-6 signal transduction through the SHP2 recruitment site of gp130. J Biol Chem 275:12848-12856, 2000. (Pubitemid 30241440)
40. Sommer U, Schmid C, Sobota RM, Lehmann U, Stevenson NJ, Johnston JA, Schaper F, Heinrich PC and Haan S: Mechanisms of SOCS3 phosphorylation upon interleukin-6 stimulation. Contributions of Src-and receptor-tyrosine kinases. J Biol Chem 280:31478-31488, 2005. (Pubitemid 41291890)